

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Arcion Therapeutics, Inc.	11/05/2010
RECEIVING PARTY DATA	
Name:	Vallinex, Inc.
Street Address:	2400 Boston Street
Internal Address:	Suite 330
City:	Baltimore
State/Country:	MARYLAND
Postal Code:	21224
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11499995
CORRESPONDENCE DATA	
Fax Number:	(404)879-2160
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	404-879-2150
Email:	margaret@pabstpatent.com
Correspondent Name:	Pabst Patent Group LLP
Address Line 1:	1545 Peachtree Street NE
Address Line 2:	Suite 320
Address Line 4:	Atlanta, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	VAL 1007 DIV
NAME OF SUBMITTER:	Rivka D. Monheit
Total Attachments: 6 source=VAL 1007 DIV Assignment#page1.tif source=VAL 1007 DIV Assignment#page2.tif	

CH \$40.00 11499995

501362353

PATENT
REEL: 025416 FRAME: 0718

source=VAL 1007 DIV Assignment#page3.tif
source=VAL 1007 DIV Assignment#page4.tif
source=VAL 1007 DIV Assignment#page5.tif
source=VAL 1007 DIV Assignment#page6.tif

ASSIGNMENT

Arcion Therapeutics, Inc., a corporation of the State of Delaware, having its principal place of business at 2400 Boston Street, Suite 330, Baltimore, Maryland 21224 (hereinafter "Assignor") in consideration of ten dollars and other valuable consideration paid by Vallinex, Inc., a corporation of the State of Delaware, having its principal place of business at 2400 Boston Street, Suite 330, Baltimore, Maryland 21224 (hereinafter "Assignee"), the receipt of which is hereby acknowledged, does hereby sell, assign and transfer unto Assignee, its successors and assigns, the entire interest for the United States of America, and its territories and all foreign countries and jurisdictions, including all rights of priority under the International Convention for the Protection of Industrial Property, in certain inventions or improvements identified in Schedule A, attached hereto (collectively, the "Patents and Patent Applications"), and in all Letters Patent of the United States and its territories and all foreign countries and jurisdictions which may or shall be granted on the Patents and Patent Applications, or any provisional, divisional, continuation, reissue, or other applications based thereon. Assignor agrees, for itself and its successors and assigns, with Assignee and its successors and assigns, but at its expense or charges, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and its territories and in all other foreign countries and jurisdictions to Assignee, with specifications and claims in such form as shall be approved by the counsel of Assignee, and to vest and confirm in Assignee, its successors and assigns, the legal title to all said Patents and Patent Applications.

ACCEPTANCE OF ASSIGNMENT

Vallinex, Inc. does hereby declare that it has accepted from Arcion Therapeutics, Inc., the Assignment of rights in certain inventions or improvements described in the attached Schedule A including all rights of priority, and in all Letters Patent of the United States and its territories and all foreign countries and jurisdictions which may or shall be granted on the inventions, or any parts thereof, or any provisional, divisional, continuation, continuation-in-part, reissue, or other applications based in whole or in part thereon.

WITNESS my hand and seal this 5th day of November, 2010.

VALLINEX, INC.

KERRIE BRADY
Name
[Signature]
Signature
CHIEF OPERATIONS OFFICER
Title

State of Maryland
County of Baltimore

Then personally appeared the above named Kerrie Brady, and attested that he/she is authorized to execute documents on behalf of Vallinex, Inc., and acknowledged the foregoing instrument to be his/her free act and deed, before me this 5 day of November, 2010.

My Commission expires: 8/15/2013

Valerie E Ellis
Notary Public

Assignment from Arcion Therapeutics, Inc.
to Vallinex, Inc.

Assignor does hereby authorize and request the Commissioner of Patents and
Trademarks of the United States to issue such Letters Patent as shall be granted upon said
Patents and Patent Applications based thereon to Assignee, its successors and assigns.

IN WITNESS WHEREOF, the Assignor has caused this instrument to be executed by its
duly authorized representative this 5th day of November, 2010.

ARCION THERAPEUTICS, INC.

KERRIE BRADY
Name
[Signature]
Signature
CHIEF OPERATIONS OFFICER
Title

State of Maryland
County of Baltimore

Then personally appeared the above named Kerrie Brady and attested that
he/she is authorized to execute documents on behalf of Arcion Therapeutics, Inc., and
acknowledged the foregoing instrument to be his/her free act and deed, before me this 5
day of November, 2010.

Valerie E Ellis
Notary Public

My Commission expires: 8/15/2013

SCHEDULE A
Patent Rights Assigned by Arcion Therapeutics, Inc. to Vallinex, Inc.

No.	PPG Docket No.	Country	Application Serial No./Publication No.	Date Filed	Patent No.	Issue Date
1.		US	60/461,164	04/08/2003		
2.		US	60/434,530	12/18/2002		
3.		US	60/434,501	12/18/2002		
4.		US	60/434,500	12/18/2002		
5.		US	60/434,453	12/18/2002		
6.		US	60/434,452	12/18/2002		
7.		US	60/434,828	12/18/2002		
8.	VAL 1004	US	10/742,441	12/18/2003		
9.	VAL 1004 CON	US	12/287,746	10/14/2008		
10.	VAL 1007	US	10/742,621	12/18/2003		
11.	VAL 1007 DIV	US	11/499,995	08/07/2006		
12.	VAL 1007 CON	US	12/077,494	03/18/2008		
13.	VAL 1007	PCT	PCT/US03/40356	12/18/2003		
14.	VAL 1007	AR	P05-01-02460	12/18/2003		
15.	VAL 1007	AU	2003299691	12/18/2003	2003299691	06/05/2008
16.	VAL 1007	BR	20030016906	12/18/2003		
17.	VAL 1007	CA	2510181	12/18/2003		
18.	VAL 1007	CN	200380109828.0	12/18/2003		
19.	VAL 1007 DIV	CN	200910164452.2	12/18/2003		
20.	VAL 1007	EA	200500986	12/18/2003	EA011708	04/28/2009
21.	VAL 1007	EP	03799973.7	12/18/2003		
22.	VAL 1007	IL	169214	12/18/2003		
23.	VAL 1007	IN	2648/DELNP/2005	12/18/2003		
24.	VAL 1007 DIV	IN	8523/DELNP/2008	10/10/2008		
25.	VAL 1007	JP	2005-510006	12/18/2003		
26.	VAL 1007	MX	006670	12/18/2003		
27.	VAL 1007	NZ	540769	12/18/2003	540769	07/31/2009
28.	VAL 1007 DIV	NZ	574630	02/02/2009		
29.		US	60/531,074	12/18/2003		
30.	VAL 1009	US	10/821,473	04/08/2004		
31.	VAL 1009 DIV	US	11/880,990	07/25/2007		
32.	VAL 1009	PCT	PCT/US04/10745	04/08/2004		
33.	VAL 1009	AR	P05-01-04230	04/08/2004		
34.	VAL 1009	AU	2004230915	04/08/2004	2007230915	07/08/2008
35.	VAL 1009	BR	2004PI09748	04/08/2004		
36.	VAL 1009	CA	2521925	04/08/2004		
37.	VAL 1009	CN	200480015966.7	04/08/2004	100500142	06/17/2009
38.	VAL 1009	EA	200501582	04/08/2004		

SCHEDULE A CONTINUED

No.	PPG Docket No.	Country	Application Serial No./Publication No.	Date Filed	Patent No.	Issue Date
39.	VAL 1009	EP	04749854.8	04/08/2004		
40.	VAL 1009	IL	171282	04/08/2004		
41.	VAL 1009	IN		04/08/2004		
42.	VAL 1009	JP	20060509790	04/08/2004		
43.	VAL 1009	MX	MX2005PA10882	04/08/2004		
44.	VAL 1009	NZ	542887	04/08/2004	542887	09/26/2008
45.	VAL 1009	AM	200501582	04/08/2004		
46.	VAL 1009	AZ	200501582	04/08/2004		
47.	VAL 1009	BY	200501582	04/08/2004		
48.	VAL 1009	KG	200501582	04/08/2004		
49.	VAL 1009	KZ	200501582	04/08/2004		
50.	VAL 1009	MD	200501582	04/08/2004		
51.	VAL 1009	RU	200501582	04/08/2004		
52.	VAL 1009	TJ	200501582	04/08/2004		
53.	VAL 1009	TM	200501582	04/08/2004		
54.	VAL 1013	US	10/741,197	12/18/03		
55.	VAL 1013 CON	US	12/288,019	10/16/2008		
56.	VAL 1014	US	10/741,196	12/18/2003		
57.	VAL 1014 CON	US	12/288,033	10/16/2008		
58.	VAL 1019	US	10/741,194	12/18/2003		
59.	VAL 1019 CON	US	12/288,020	10/16/2008		
60.	VAL 1020	US	10/742,443	12/18/2003		
61.	VAL 1020 CON	US	12/228,226	08/11/2008		
62.	VAL 1027	PCT	PCT/US03/40766	12/18/2003		
63.	VAL 1027	AU	0301190	12/18/2003		
64.	VAL 1027	AT	0813821	12/18/2003	AT401874	08/15/2008
65.	VAL 1027	DK	0813821	12/18/2003	DK1587506	11/24/2008
66.	VAL 1027	EP	03813821.0	12/18/2003	EP1587506	07/23/2008
67.	VAL 1027	ES	030813821	12/18/2003	ES2311756	02/16/2009
68.	VAL 1027	JP	2005-502659	12/18/2003		
69.	VAL 1027	PT	0813821T	12/18/2003	PT1587506	10/30/2008
70.	VAL 1027	SI	20030031389	12/18/2003	SI1587506	04/30/2009
71.	VAL 1027	BG	0813821	12/18/2003		
72.	VAL 1027	CH	0813821	12/18/2003		
73.	VAL 1027	CY	0813821	12/18/2003		
74.	VAL 1027	CZ	0813821	12/18/2003		
75.	VAL 1027	DE	0813821	12/18/2003	60322436	
76.	VAL 1027	FI	0813821	12/18/2003		

SCHEDULE A CONTINUED

No.	PPG Docket No.	Country	Application Serial No./Publication No.	Date Filed	Patent No.	Issue Date
77.	VAL 1027	FR	0813821	12/18/2003		
78.	VAL 1027	GR	0813821	12/18/2003		
79.	VAL 1027	HU	0813821	12/18/2003		
80.	VAL 1027	IE	0813821	12/18/2003		
81.	VAL 1027	IT	0813821	12/18/2003		
82.	VAL 1027	LU	0813821	12/18/2003		
83.	VAL 1027	MC	0813821	12/18/2003		
84.	VAL 1027	NL	0813821	12/18/2003		
85.	VAL 1027	RO	0813821	12/18/2003		
86.	VAL 1027	SE	0813821	12/18/2003		
87.	VAL 1027	SK	0813821	12/18/2003		
88.	VAL 1027	UK	0813821	12/18/2003		
89.	VAL 1028	US	10/741,195	12/18/2003		
90.	VAL 1028 DIV	US	11/499,989	08/02/2006		
91.	VAL 1028 CON(2)	US	12/077,492	03/18/2008		
92.		US	60/630,577	11/24/2004		
93.	VAL 1034	US	11/286,059	11/23/2005		
94.	VAL 1034	PCT	PCT/US05/42578	11/23/2005		
95.	VAL 1034	AR		11/23/2005		
96.	VAL 1034	AU	2005309586	11/23/2005		
97.	VAL 1034	BR	PI0516912	11/23/2005		
98.	VAL 1034	CA	2596194	11/23/2005		
99.	VAL 1034	CN	2005800471	11/23/2005		
100.	VAL 1034	EA	20070001131	11/23/2005		
101.	VAL 1034	EP	5853319.1	11/23/2005		
102.	VAL 1034	IL	183332	11/23/2005		
103.	VAL 1034	IN	3852/DELNP/2007	11/23/2005		
104.	VAL 1034	JP	2007543484	11/23/2005		
105.	VAL 1034	MX	MX20070006253	11/23/2005		
106.	VAL 1034	NZ	555331	11/23/2005		
107.	VAL 1035	US	61/136,545	09/12/2008		
108.	VAL 1035	US	12/559,071	09/14/2009		
109.	VAL 1035	PCT	PCT/US08/10706	09/12/2008		
110.		US	61/193,790	12/23/2008		
111.		US	61/180,263	05/21/2009		